Another giant joined the ranks of new coronavirus vaccine research and development! The novel coronavirus vaccine is accelerated by Sanofi using gene recombination technology platform.

February 20, 2020 / bioun / -- Sanofi Pasteur, the global vaccine division of Sanofi, recently announced that it will use its previous experience in developing SARS vaccine to accelerate the development of new coronavirus (covid-19) vaccine by using advanced gene recombination technology platform in cooperation with BARDA It is worth mentioning that Sanofi is another global pharmaceutical giant that has recently joined the research and development of new coronavirus vaccine after Johnson & Johnson Gene recombination technology can produce precise gene matching for the proteins on the surface of virus DNA sequence coding will be combined into the baculovirus expression platform DNA, and used to rapidly produce a large number of coronavirus antigens, which will stimulate the human immune system to resist the virus Compared with the traditional vaccine development platform, gene recombination technology is conducive to rapid development of vaccines, and large-scale preparation of vaccines in a shorter time Based on baculovirus expression platform, Sanofi has developed a recombinant influenza vaccine product which has been approved for marketing David Loew, global head of Sanofi vaccine, said: "we have to work together to deal with global health threats, such as the latest coronavirus To this end, we are working with BARDA to accelerate the development of this potential vaccine candidate We will try our best to give full play to our professional advantages We believe that cooperation will bring the most meaningful results and protect the public from the new coronavirus " China China novel coronavirus pneumonia Senauer Faye Basudeb said: "since the outbreak of the new crown pneumonia, Senauer Faye Basudeb has been paying close attention to and supporting China's epidemic prevention and control work" Zhang Heping China's participation in the novel coronavirus pneumonia vaccine is a practical commitment to protect the health of the Chinese people Based on Sanofi Pasteur's deep accumulation in the field of vaccines, we look forward to working with all parties to bring vaccines against the new coronavirus to the Chinese people as soon as possible "Novel coronavirus and other emerging global health threats such as the 2019 new BARDA need to be responded quickly," said Dr Rick A Bright, director of the new director By expanding our partnership with Sanofi Pasteur and leveraging the existing recombinant vaccine platform, we hope to accelerate the development of candidate vaccines to protect against new viruses " Sanofi has unique advantages in the field of coronavirus vaccine covid-19 belongs to the coronavirus family, which can cause respiratory diseases At the end of 2002, SARS coronavirus appeared, and then disappeared in 2004 Sanofi plans to further study a pre clinical candidate vaccine for SARS to prevent covid-19 In non clinical studies, SARS vaccine candidates have shown immunogenicity, and play a part of protective role in animal models The development of protein sciences (acquired by Sanofi in 2017) provided a start for accelerating the development of covid-19 vaccine In addition, as the platform has produced a flu vaccine approved for marketing in the United States, flublock ® will be able to be used in the production of clinical trial samples relatively quickly Sanofi's platform also has the potential to produce a large number of candidate vaccines Sanofi's long-term commitment to the protection of public health and the agreement reached with BARDA is a new milestone, which further demonstrates Sanofi's continuous contribution to the fight against public health threats Sanofi will continue to actively explore potential opportunities The company's rich vaccine development experience and innovative technology will help solve the public health problems caused by coronavirus Sanofi will share its vaccine research and development experience with the Alliance for epidemic prevention and innovation In December 2019, Sanofi also signed an agreement with BARDA to establish advanced production facilities and continue to produce adjuvant recombinant vaccine to prevent influenza pandemic The technology platform of this product will be used for the development of covid-19 vaccine Source: Sanofi group